Compare ALIT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | KMDA |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.4M | 460.3M |
| IPO Year | 2020 | 2013 |
| Metric | ALIT | KMDA |
|---|---|---|
| Price | $0.75 | $7.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $3.75 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 25.6M | 54.0K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 21.33% | 3.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,000,000.00 | N/A |
| Revenue This Year | N/A | $13.94 |
| Revenue Next Year | $0.14 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $6.50 |
| 52 Week High | $6.03 | $9.35 |
| Indicator | ALIT | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 28.92 |
| Support Level | $0.67 | $6.87 |
| Resistance Level | $1.01 | $7.41 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 6.43 | 0.56 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.